Canine Arthritis Treatment Market Size - By Treatment Type, By Arthritis Type, Growth Forecast, 2026 - 2035

Canine Arthritis Treatment Market Size

The global canine arthritis treatment market was valued at USD 3.8 billion in 2025. The market is expected to grow from USD 4 billion in 2026 to USD 7.9 billion in 2035, growing at a CAGR of 7.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

The growth of the canine arthritis treatment market is primarily driven by the significant increase in the prevalence of osteoarthritis (OA) in dogs. For instance, according to veterinary epidemiology data by VetTriage, nearly 20% of the adult canine pet population spontaneously develops osteoarthritis, equating to approximately 11–15 million dogs in the U.S. and another 5 million in Europe. Osteoarthritis (OA) is widely recognized as the most common type of arthritis in dogs and is a chronic condition that requires sustained therapy to restore mobility and joint function, thereby driving the market growth.
 

Canine arthritis treatment refers to a combination of therapies that help in managing joint pain, inflammation, and mobility loss in dogs suffering from osteoarthritis or other joint conditions. The goal of such treatments is to reduce discomfort, improve joint function, and enhance the dog’s overall health through personalized and multimodal management strategies tailored to the severity of the disease. Key players driving the growth of the market include Zoetis, Elanco Animal Health, Ceva Santé Animale, Boehringer Ingelheim Animal Health, and Virbac, among others. These players are heavily investing in research and development to launch innovative therapies such as pet monoclonal antibodies and regenerative treatments at the same time as they are expanding their distribution network to capture emerging markets.
 

From 2022 to 2024, the global canine arthritis treatment market witnessed considerable growth to reach USD 3.6 billion in 2024 from USD 3.3 billion in 2022, driven by several factors such as a growing pet population, increased willingness to spend more on animal healthcare, and rising awareness among pet owners about early diagnosis and long-term management. Moreover, the market expansion was further supported by the adoption of multimodal treatment approaches, including pharmaceuticals, nutritional supplements, physical therapy, and emerging biologic therapies.
 

Canine arthritis treatment includes pharmaceutical options like NSAIDs, corticosteroids, opioid pain relievers, and newer treatments such as monoclonal antibodies, nutritional supplements such as glucosamine and omega-3 fatty acids, physical therapy, and, occasionally, surgical procedures. These combined strategies are tailored to the severity of the condition and the individual needs of the dog, aiming to maintain mobility, reduce pain, and support long-term joint health.
 

Canine Arthritis Treatment Market Trends

• The increasing demand for monoclonal antibody therapies is one of the major trends for significant market growth in the canine arthritis treatment market. These monoclonal antibody therapies targeting pain pathways are gaining traction owing to their long-lasting relief with fewer side effects as compared to traditional NSAIDs. Thus, an increasing number of animal health companies are investing in research and development of monoclonal antibodies for arthritis treatment in dogs.
   

• For instance, in October 2025, Zoetis disclosed that Lenivia (izenivetmab injection) was approved by Health Canada for treating the pain of osteoarthritis in dogs. Such regulatory approvals are resulting in greater adoption of monoclonal antibodies and other canine arthritis treatment options.
   

• Additionally, nutritional supplements including glucosamine, chondroitin, and omega-3 fatty acids are also being adopted at a faster pace as a result of the rising awareness of preventive health, safety, and long-term joint support.
   
• Further, emerging markets in the Asia Pacific and Latin America are expanding rapidly due to the rising disposable incomes, improving veterinary healthcare infrastructure, increasing pet population, and the willingness of pet owners to spend on animal healthcare.
   
• For instance, as per the World Population Review 2025, China has around 54.3 million dog population. Similarly, according to Pet Data, urban Chinese pet owners spent approximately USD 41 billion on their cats and dogs in 2024, a 7.5% annual increase. Such a high population is creating new opportunities for both canine pharmaceuticals and supplements.
   
• Moreover, increased accessibility of medications as well as supplements through digital platforms and e-commerce channels is enabling recurring revenue and wider market penetration.
   
• Collectively, these factors are expected to drive sustained growth in the canine arthritis treatment market by enhancing treatment accessibility, improving long-term disease management, and expanding care reach across diverse geographic regions.
   

Canine Arthritis Treatment Market Analysis

The canine arthritis treatment market was valued at USD 3.3 billion and USD 3.5 billion in 2022 and 2023, respectively. The market size reached USD 3.8 billion in 2025, growing from USD 3.6 billion in 2024.

Based on the treatment type, the market is segmented into non-surgical treatment, surgical procedure, and other treatment types. The non-surgical treatment dominated the market with a market share of 77.1% and was valued at USD 2.9 billion in 2025.
 

The dominant market share of this segment is mainly due to the increasing preference for non-invasive treatment approaches such as medications, monoclonal antibodies, physical therapy, and nutritional supplements before considering surgical intervention. Additionally, the cost-effectiveness of non-surgical treatment compared to surgical interventions makes them accessible to a broader pet population, especially for long-term disease management. Further, the increasing awareness and importance of disease prevention and progression control among pet owners is driving the adoption of supplements as well as pharmaceuticals.

On the other hand, the surgical procedures segment is expected to grow at 7.6% CAGR during the forecast period. Many dogs with arthritis that progress to advanced stages often require surgical intervention for long-term pain relief and mobility restoration. Additionally, expansion of referral hospitals and specialty clinics equipped with advanced surgical infrastructure, coupled with growing adoption of pet insurance, further support the growth of this segment.
 

Based on the arthritis type, the canine arthritis treatment market is classified into osteoarthritis, traumatic arthritis, osteochondrosis, and rheumatoid arthritis. The osteoarthritis segment dominated the market with 56.9% of market share in 2025.
 

• Osteoarthritis is a common degenerative joint disease in dogs, significantly contributing to the overall burden of canine arthritis, thereby driving the need for effective treatment options.
   
• For instance, as per an article published by Virbac, 1 in 5 dogs over the age of one is affected by this condition, highlighting its early onset and widespread prevalence. The incidence further increases with age, with approximately 20 - 30% of the senior canine population suffering from osteoarthritis.
   
• This rising prevalence of OA across different age groups underscores the substantial demand for long-term management solutions, positioning osteoarthritis as the leading segment in the canine arthritis treatment market.
   
• On the other hand, the traumatic arthritis segment is predicted to grow at 7.7% CAGR during the analysis timeframe. As dogs are more engaged in agility training, hunting, and other physical activities, the risk of joint trauma and injuries is significantly high, thereby necessitating the adoption of canine arthritis treatment.
   
• Additionally, increasing obesity in dogs is also resulting in traumatic arthritis as overweight dogs are more prone to falls, ligament tears, and fractures, thereby expanding the patient base and driving adoption of these treatments.
   

North America Canine Arthritis Treatment Market
 

North America dominated the canine arthritis treatment industry with a market share of 43.3% in 2025.
 

• The growth of this region is driven by a combination of high pet ownership, strong spending on pet healthcare, and advanced veterinary infrastructure.
   
• For instance, as per the American Pet Products Association, in 2024, USD 152 billion was spent on pets in the U.S., demonstrating increased willingness of pet owners in this region to invest in high-quality care and innovative treatments for companion animals, including dogs.
   
• Additionally, a well-established network of veterinary clinics, specialty hospitals, and diagnostic centers across North America supports early diagnosis and long-term management of chronic conditions in dogs, including arthritis.
   

The U.S. canine arthritis treatment market was valued at USD 1.33 billion and USD 1.38 billion in 2022 and 2023, respectively. The market size reached USD 1.52 billion in 2025, growing from USD 1.45 billion in 2024.
 

• The dominant market position of the U.S. can be attributed to the rising prevalence of arthritis in aging canine populations, supported by increasing pet lifespans and improved diagnostic capabilities.
   
• For instance, according to the survey data published in the recent Packaged Facts report, almost half, or around 47%, of American dog owners have a dog age 7 or older. As a result, the growing elderly canine population is expected to significantly increase demand for long-term arthritis management therapies and supportive care solutions in the country.
   
• Additionally, increased adoption of digital veterinary services and telehealth improves follow-up care, treatment adherence, and access to arthritis management.
•  

Europe Canine Arthritis Treatment Market

Europe canine arthritis treatment market accounted for USD 946.6 million in 2025 and is anticipated to witness lucrative growth over the forecast period.

• The increasing prevalence of obesity in the canine population in Europe is a major risk factor for osteoarthritis.
•  
• For instance, several studies indicate a significant portion of European dogs are overweight, with one major survey finding owner-reported overweight/obesity rates from 31.8% to 69.4% depending on the measurement method.
   
• Additionally, European countries such as Germany, the UK, France, and Italy are witnessing a growing aging pet population, along with heightened pet owner awareness of mobility disorders and chronic pain management.
   
• Moreover, the supportive regulatory frameworks and growing investments in veterinary medicine and R&D of novel drugs are further contributing to the growth of this market.
   

Germany dominates the Europe canine arthritis treatment market, showcasing strong growth potential over the forecast years.
 

• As per the Pet Food Industry, in 2022, the dog population of Germany was around 10.6 million. Coupled with increasing pet owner awareness regarding mobility disorders, obesity-related risks, and long-term health management, this large population is driving demand for effective, long-term canine arthritis treatments, thereby supporting steady market growth in Germany and contributing to the broader European market expansion.
   
• Moreover, the presence of leading veterinary pharmaceutical companies and distributors, along with strong regulatory standards, ensures wide availability and rapid uptake of novel canine arthritis treatments.
   

Asia Pacific Canine Arthritis Treatment Market

The Asia Pacific canine arthritis treatment industry is anticipated to grow at the highest CAGR of 8.3% during the analysis timeframe.
 

• In the Asia Pacific countries such as China, Japan, and India, the dog population is significantly growing.
   
• For instance, as per Statista, the overall population of pet dogs in India was over 33 million in 2023, which is expected to grow and reach more than 51 million by 2028. This growing pet dog population, along with increased spending on animal health, is driving the adoption of canine arthritis treatment.
   
• In addition, the region is witnessing significant improvements in veterinary training and clinical standards, with increasing adoption of international treatment guidelines and advanced pain-management protocols.
   
• Also, growing adoption of digital veterinary platforms, teleconsultations, and e-commerce distribution of pet medications and supplements are improving accessibility, especially in densely populated urban areas, thus contributing to market growth.
   

China canine arthritis treatment market is estimated to grow with a significant CAGR in the Asia Pacific market.

• According to Euromonitor data cited by China International Capital Corporation (CICC) analysts, China had over 27,000 pet hospitals and clinics in 2023, highlighting the rapid expansion of veterinary services. This growing infrastructure improves access to diagnosis and long-term care for chronic conditions such as canine arthritis.
   
• Further, a combination of institutional efforts and the rapidly evolving veterinary medicine market is fostering the growth of the Chinese canine arthritis market landscape.
   
• For example, veterinary associations and animal welfare organizations, such as the Chinese Veterinary Medical Association (CVMA), China Animal Health and Food Safety Alliance, and various regional pet welfare foundations, are actively promoting the awareness of different animal health issues, age-related disorders, as well as preventive healthcare for animals, thereby driving the adoption of effective treatments.
   
• Additionally, the entry of international veterinary pharmaceutical manufacturers, as well as increasing domestic manufacturers, further boosts the availability of advanced treatment options.
   

Latin American Canine Arthritis Treatment Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• With Brazil’s vast companion-animal base and strong cultural trend of viewing dogs as family members, the market for chronic conditions such as arthritis continues to expand.
   
• As per an article published by Valor International, in 2021, Brazil owned 168 million pets, of which 68 million were dogs. Further, as per an article published by the National Institutes of Health, a survey estimated the combined prevalence of obesity and overweight of 40.0% in the canine population of Brazil.
   
• Such high dog populations, along with the increasing prevalence of obesity and overweight highlights a large patient pool susceptible to degenerative joint disorders. Thus, creating sustained demand for long-term canine arthritis diagnosis, treatment, and management solutions across the country.
   
• Additionally, expansion of veterinary clinics, specialty practices, and diagnostic services across the country is improving access to treatment and increasing early-stage arthritis care.
   

Middle East and Africa Canine Arthritis Treatment Market
 

Saudi Arabia canine arthritis treatment industry is expected to experience substantial growth in the Middle East and Africa market.
 

• The market growth is supported by the growing awareness of canine mobility disorders among pet owners and veterinarians, along with increasing access to modern veterinary clinics and specialty animal hospitals across major cities such as Riyadh, Jeddah, and Dammam.
   
• Rising disposable incomes and higher spending on premium pet healthcare products and services are also contributing to greater adoption of arthritis treatments.
   

Canine Arthritis Treatment Market Share

Leading companies such as Zoetis, Elanco Animal Health, Boehringer Ingelheim, Dechra Pharmaceuticals, and Virbac account for approximately 57.2% of the global market share by focusing on the development of next-generation therapies for canine osteoarthritis and joint pain management. Innovations in monoclonal antibodies, disease-modifying osteoarthritis drugs (DMOADs), regenerative therapies, and long-acting NSAID formulations are driving clinical advancement and improving treatment adherence among pet owners.
 

Additionally, collaborations with veterinary institutions, licensing of novel biologics, and partnerships with nutraceutical and supplement companies are accelerating the introduction of innovative solutions that target inflammation, cartilage degradation, and pain relief. Many companies are also increasing investments in research and development to create safer, more effective, and longer-lasting treatments, while improving accessibility and affordability. Efforts to expand veterinary services in emerging regions and raise awareness among pet owners further highlight the market’s shift toward comprehensive, personalized care for companion animals.
 

Canine Arthritis Treatment Market Companies

Prominent players operating in the canine arthritis treatment industry are as mentioned below:

• AdvaCare Pharma
• American Regent
• Auburn Laboratories
• Boehringer Ingelheim Animal Health
• CEVA Santé Animale
• Dechra Pharmaceuticals
• Deley Naturals
• Elanco Animal Health
• K9 Vitality
• Norbrook Laboratories
• Nutramax Laboratories Veterinary Sciences
• Thorne Vet
• Vetoquinol
• VetriScience
• VetStem
• Virbac
• Zoetis
   

Zoetis

Zoetis holds a leading position accounting for ~18.4% in the canine arthritis treatment market, driven by its strong portfolio of biologics and NSAID therapies, including Librela (bedinvetmab) and other joint health solutions. The company has emphasized innovation in monoclonal antibodies targeting pain and inflammation, addressing critical needs in osteoarthritis management and long-term mobility support for aging dogs. Zoetis’s extensive global distribution network and strong relationships with veterinary practices have solidified its market leadership and adoption of advanced therapies.
 

Elanco Animal Health

Elanco has established a significant presence in the canine arthritis market through its flagship NSAID, Galliprant and complementary pain-management solutions. The company focuses on safe, targeted inhibition of prostaglandin-mediated inflammation, offering veterinarians effective options for chronic arthritis care. Strategic acquisitions and expansion of veterinary channels have enhanced Elanco’s ability to reach both urban and emerging markets, strengthening its footprint in global canine osteoarthritis management.
 

Boehringer Ingelheim

Boehringer Ingelheim has made a notable impact on the canine arthritis market with its broad portfolio of pain-relief and anti-inflammatory products, including Metacam (meloxicam). The company emphasizes clinically proven, long-term management options for joint disorders and works closely with veterinary specialists to optimize dosing and treatment protocols. By expanding product availability across key regions and investing in veterinary education, Boehringer Ingelheim has reinforced its reputation as a trusted partner for canine arthritis care.
 

Canine Arthritis Treatment Market Industry News

• In October 2025, Zoetis received Health Canada approval for Lenivia (izenivetmab injection) for managing pain associated with osteoarthritis in dogs, strengthening its biologics portfolio in the Canadian veterinary market. This approval enabled Zoetis to expand its geographic footprint and drive additional revenue through a differentiated monoclonal antibody therapy for chronic canine pain management.
   
• In March 2025, Can-Fite BioPharma announced that its veterinary partner Vetbiolix initiated an advanced clinical study evaluating oral Piclidenoson as a daily treatment for osteoarthritis in dogs. The study supports pipeline diversification and creates a potential new revenue stream by extending Can-Fite’s proprietary small-molecule platform into the veterinary therapeutics segment.
   
• In February 2025, Zoetis updated the U.S. label for Librela (bedinvetmab injection) following FDA approval of a supplemental submission, reflecting expanded or clarified usage information. The label update enhanced physician confidence, broadened clinical adoption, and reinforced Zoetis’s leadership in the canine osteoarthritis biologics market in the U.S.
   
• In December 2022, Norbrook launched Firox (firocoxib) chewable tablets, offering an effective, affordable, and convenient NSAID option for canine pain and inflammation management. This launch strengthened Norbrook’s competitive position in the cost-sensitive NSAID segment while expanding its product portfolio for veterinarians and pet owners seeking accessible arthritis treatments.
   

The canine arthritis treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Non-surgical treatment
• By type
• Pharmaceuticals
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids
• Opioid pain relievers
• Other pharmaceuticals
• Supplements
• Glucosamine
• Chondroitin
• Methylsulfonylmethane
• Other supplements
• By route of administration
• Oral
• Injectable
• Other routes of administration
• By distribution channel
• Veterinary hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Surgical procedures
• Other treatment types

Market, By Arthritis Type

• Osteoarthritis
• Traumatic arthritis
• Osteochondrosis
• Rheumatoid arthritis

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE